A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Shadia Jalal, MD
Primary Investigator
Overview
The purpose of this study is to perform two tests to test for two particular types of biomarkers (i.e. protein, DNA or RNA) in the body to see if someone might be suitable for a genetically changed T cell treatment.
Description
The study will assess a subject's human leukocyte antigen (HLA) subtype and tumor antigen expression profile. Based on the results, it will be determined if a subject is eligible to be considered for Adaptimmune sponsored clinical trials testing the safety and efficacy of genetically changed T cells targeting specific tumor antigens.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
lung cancer,myeloma,melanoma,non-small cell lung cancer,head and neck cancer,gastric cancer,bladder cancer,Solid and Hematological Malignancies
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
Histologically or cytologically confirmed diagnosis of advanced solid or hematologic malignancy or recurrent disease, as described in the respective Adaptimmune clinical treatment protocol (including, but not limited to myeloma, melanoma, NSCLC, head and neck, gastric and bladder cancer)
Ability to provide a blood sample
Ability to provide a tumor tissue sample
Exclusion Criteria
Any bleeding diathesis or coagulopathy, which at the discretion of the Investigator may put the subject at risk
Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the screening study procedures